ClinicalTrials.gov
ClinicalTrials.gov Menu

Follow up of Autoantibodies in Active Tuberculosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00551226
Recruitment Status : Unknown
Verified October 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : October 30, 2007
Last Update Posted : October 30, 2007
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center

Brief Summary:
We have previoulsy shown that patients with active Tuberculosis develop a wide array of autoantibodies including rheumatoid factor, anti-CCP, Antinuclear facyor and anti Sm antibodies. The purpose of this study is to evaluate whether the level of autoantibodies decrease after treatment aganist tuberculosis.

Condition or disease
Tuberculosis

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Follow up of Autoantibodies in Active Tuberculosis
Study Start Date : November 2007
Estimated Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis
U.S. FDA Resources

Group/Cohort
1
Patients with tuberculosis
2
Healthy controls



Primary Outcome Measures :
  1. Follow up after levels of autoantibodies [ Time Frame: 1 year ]

Biospecimen Retention:   Samples Without DNA
Serum of patients


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with active tuberculosis who are currently receiving anti tuberculosis drugs
Criteria

Inclusion Criteria:

  • Active Tuberculosis treated

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00551226


Contacts
Contact: Ori Elkayam, M.D 97236973668 oribe14@netvision.net.il

Locations
Israel
Tel Aviv Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Contact: Ori Elkayam, M.D    97236973668    oribe14@netvision.net.il   
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: Ori Elkayam, M.D Tel Aviv Medical Center

ClinicalTrials.gov Identifier: NCT00551226     History of Changes
Other Study ID Numbers: 314-07
First Posted: October 30, 2007    Key Record Dates
Last Update Posted: October 30, 2007
Last Verified: October 2007

Keywords provided by Tel-Aviv Sourasky Medical Center:
TB
Patients with tuberculosis

Additional relevant MeSH terms:
Tuberculosis
Latent Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Autoantibodies
Immunologic Factors
Physiological Effects of Drugs